Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.67 |
| ▸ | FAAH | O00519 | 3/20 | 0.59 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.59 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.55 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.46 |
| ▸ | GAPDH | P04406 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | FDPS | P14324 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19816345 | 1.00 | TSHR (0.67) | TSHRFAAHTRPV1FFAR4FFAR1 | |
| SCHEMBL15508284 | 1.00 | TSHR (0.67) | TSHRFAAHTRPV1FFAR4FFAR1 | |
| SCHEMBL1303096 | 1.00 | TSHR (0.67) | TSHRFAAHTRPV1FFAR4FFAR1 | |
| SCHEMBL11798450 | 1.00 | TSHR (0.67) | TSHRFAAHTRPV1FFAR4FFAR1 | |
| SCHEMBL28577636 | 1.00 | TSHR (0.67) | TSHRFAAHTRPV1FFAR4FFAR1 | |
| SCHEMBL16706242 | 1.00 | TSHR (0.67) | TSHRFAAHTRPV1FFAR4FFAR1 | |
| SCHEMBL10797175 | 0.98 | TSHR (0.64) | TSHRFAAHTRPV1FFAR4FFAR1 | |
| SCHEMBL6517013 | 0.98 | TSHR (0.64) | TSHRFAAHTRPV1FFAR4FFAR1 | |
| SCHEMBL21530621 | 0.96 | TSHR (0.60) | TSHRFAAHTRPV1FFAR4FFAR1 | |
| SCHEMBL7913952 | 0.92 | FFAR4 (0.55) | TSHRFAAHTRPV1FFAR4FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11883399-B2 | Bromocriptine formulations | VEROSCIENCE LLC (US) | 2024-01-30 | — | — | US | claimed |
| EP-4233913-A2 | IMPROVED BROMOCRIPTINE FORMULATIONS | VeroScience LLC (US) | 2023-08-30 | — | — | EP | claimed |
| US-11680228-B2 | Amides of aliphatic polyamines and 12-hydroxyoctadecanoic acid and lipase stable thickener compositions | EVONIK OPERATIONS GMBH (DE) | 2023-06-20 | — | — | US | claimed |
| US-20210177839-A1 | IMPROVED BROMOCRIPTINE FORMULATIONS | VEROSCIENCE LLC | 2021-06-17 | — | — | US | claimed |
| CN-108699491-B | Amide of aliphatic polyamine and 12-hydroxyoctadecanoic acid and lipase-stabilized thickener composition | 赢创运营有限公司 | 2020-12-29 | — | — | CN | claimed |
| EP-3420062-B1 | AMIDES OF ALIPHATIC POLYAMINES AND 12-HYDROXYOCTADECANOIC ACID AND LIPASE STABLE THICKENER COMPOSITIONS | EVONIK OPERATIONS GMBH (DE) | 2020-05-27 | — | — | EP | claimed |
| US-20190055497-A1 | AMIDES OF ALIPHATIC POLYAMINES AND 12-HYDROXYOCTADECANOIC ACID AND LIPASE STABLE THICKENER COMPOSITIONS | EVONIK OPERATIONS GMBH (DE) | 2019-02-21 | — | — | US | claimed |
| EP-3420062-A1 | AMIDES OF ALIPHATIC POLYAMINES AND 12-HYDROXYOCTADECANOIC ACID AND LIPASE STABLE THICKENER COMPOSITIONS | Evonik Degussa GmbH (DE) | 2019-01-02 | — | — | EP | claimed |
| WO-2017144340-A1 | AMIDES OF ALIPHATIC POLYAMINES AND 12-HYDROXYOCTADECANOIC ACID AND LIPASE STABLE THICKENER COMPOSITIONS | EVONIK DEGUSSA GMBH (DE) | 2017-08-31 | — | — | WO | claimed |
| WO-2008037288-A1 | SACCHARIDE ESTERS AND THEIR USE AS SURFACTANT | TIENSE SUIKERRAFINADERIJ NV. (BE) | 2008-04-03 | — | — | WO | claimed |
| US-20030118618-A1 | New Method for making a water-in-oil emulsion | WALTER MERTON, INC. | 2003-06-26 | — | — | US | claimed |
| WO-2003034983-A2 | COMPOSITIONS AND A NEW METHOD FOR MAKING A WATER-IN-OIL EMULSION | WALTER MERTON, CO., INC. (US) | 2003-05-01 | — | — | WO | claimed |
| JP-3097781-A | — | — | None | — | — | JP | disclosed |
| US-11883399-B2 | Bromocriptine formulations | VEROSCIENCE LLC (US) | 2024-01-30 | — | — | US | disclosed |
| US-20230329986-A1 | HYDRO-ALCOHOLIC COMPOSITION FOR HAND DISINFECTION | SOCIETE D'EXPLOITATION DE PRODUITS POUR LES INDUSTRIES CHIMIQUES SEPPIC (FR) | 2023-10-19 | — | — | US | disclosed |
| US-20230321090-A1 | BROMOCRIPTINE FORMULATIONS | VEROSCIENCE LLC | 2023-10-12 | — | — | US | disclosed |
| EP-0373039-A2 | New lysoganglioside derivatives | FIDIA S.p.A. (IT) | 1990-06-13 | — | — | EP | disclosed |
| US-4814010-A | POLYESTERS, POLYLACTONES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1989-03-21 | — | — | US | disclosed |
| EP-0277711-A1 | Corrosion inhibition | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-08-10 | — | — | EP | disclosed |
| EP-0233684-A1 | Dispersing agent | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321090-A1 | BROMOCRIPTINE FORMULATIONS | PDE2A, PDE5A, MC2R | TSHR 225/4885FAAH 2020/4885TRPV1 4812/4885 |
| US-20210177839-A1 | IMPROVED BROMOCRIPTINE FORMULATIONS | PDE2A, MC2R, PDE5A | TSHR 291/4885FAAH 1956/4885TRPV1 4793/4885 |
| US-11883399-B2 | Bromocriptine formulations | PDE2A, PDE5A, MC2R | TSHR 225/4885FAAH 2020/4885TRPV1 4812/4885 |
| US-20030118618-A1 | New Method for making a water-in-oil emulsion | DEGS1, DGAT2, DGAT1 | TSHR 4076/4885FAAH 64/4885TRPV1 320/4885 |
| US-20230329986-A1 | HYDRO-ALCOHOLIC COMPOSITION FOR HAND DISINFECTION | ADH1C, HAO2, ADH1A | TSHR 2565/4885FAAH 1393/4885TRPV1 3424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.